ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,048.42
-0.46%
Dow Jones
38,085.80
-0.98%
US Dollar vs MXN
17.19491
-0.06%
Brent Oil
88.325
0.20%
Bitcoin
64,538.47
0.08%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) Noticias

AZN AstraZeneca PLC

74.78
3.58 (5.03%)
25 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
AstraZeneca PLC AZN NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
3.58 5.03% 74.78 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
74.99 74.50 75.81 75.03 71.20
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202407:00PRNUSAbelZeta Announces Abstract for C-CAR031 Accepted for..
25/4/202406:53IHMARKETNEWSU.S. Futures Drop in Pre-Market Trading as Tech Stocks..
25/4/202406:52IHMARKETNEWSSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss,..
25/4/202401:00BWQ1 2024 results
16/4/202406:00BWIMFINZI® (durvalumab) plus chemotherapy doubled overall..
12/4/202406:05IHMARKETNEWSParamount Global Board Shrinks, Morgan Stanley Faces..
11/4/202406:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
11/4/202406:00BWFASENRA approved for treatment of children aged 6 to 11 with..
05/4/202422:10BWENHERTU® Approved in the U.S. as First Tumor Agnostic HER2..
05/4/202420:43BWENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the..
05/4/202406:00BWIMFINZI® (durvalumab) significantly improved overall..
02/4/202406:00BWDatopotamab deruxtecan Biologics License Application..
02/4/202401:00BWDatopotamab Deruxtecan Biologics License Application..
01/4/202406:00BWVOYDEYA™ approved in the US as add-on therapy to ravulizumab..
27/3/202405:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
26/3/202406:20IHMARKETNEWSSuper Micro Computer and Seagate Shares Surge on Analyst..
25/3/202406:00BWULTOMIRIS® (ravulizumab-cwvz) approved in the US for the..
19/3/202406:33IHMARKETNEWSUnilever Initiates Ice Cream Division Spin-Off and Announces..
19/3/202406:00BWAstraZeneca to acquire Fusion to accelerate the development..
19/3/202405:52IHMARKETNEWSAstraZeneca to acquire Fusion for $2 billion
18/3/202406:00BWAstraZeneca caps patient out-of-pocket costs at $35 per..
14/3/202406:39IHMARKETNEWSFisker’s Shares Take a Hit Amid Speculation of Bankruptcy,..
13/3/202406:06BWAstraZeneca announces initiation of THARROS – a Phase III..
07/3/202404:43IHMARKETNEWSTesla Exits Market Top 10, Victoria’s Secret Stock Tumbles..
26/2/202415:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/2/202408:00PRNCAAlexion Canada donne de la couleur aux maladies rares avec..
26/2/202405:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/2/202415:09EDGAR2Form 424B2 - Prospectus [Rule 424(b)(2)]
23/2/202412:23BWMANDARA Phase III data published in New England Journal of..
22/2/202408:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/2/202408:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/2/202406:10BWDatopotamab deruxtecan Biologics License Application..
19/2/202406:05BWTAGRISSO® (osimertinib) demonstrated overwhelming efficacy..
19/2/202401:00BWDatopotamab Deruxtecan Biologics License Application..
16/2/202421:00BWTAGRISSO® (osimertinib) with the addition of chemotherapy..
09/2/202404:51IHMARKETNEWSCloudflare Skyrockets 26% Pre-Market; Expedia Plunges 14%..
08/2/202405:10IHMARKETNEWSArm Achieves Record Revenue, PayPal Shares Plummet by More..
08/2/202401:03BWAstraZeneca Full year and Q4 2023 Financial Results
07/2/202406:31PRNUSSOPHiA GENETICS and AstraZeneca Spain Commit to Increasing..
07/2/202405:51PRNUSSOPHiA GENETICS and AstraZeneca Spain Commit to Increasing..
06/2/202408:00BWAstraZeneca expands US manufacturing footprint to accelerate..
05/2/202408:00GLOBEYiviva Announces Memorandum of Understanding with..
29/1/202406:00BWENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority..
24/1/202416:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/1/202406:00BWAIRSUPRA® (albuterol/budesonide) now available as the first..
19/1/202409:05BWIMFINZI® (durvalumab) plus transarterial chemoembolization..
19/1/202407:46EDGAR2Form SC TO-T/A - Tender offer statement by Third Party:..
19/1/202407:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/1/202405:15IHMARKETNEWSWall Street Highlights: Apple Cuts iPhone Prices in China,..
08/1/202407:45IHNWExciting New Cures Possible from GLP-1 Diabetes, Weight-Loss..

Su Consulta Reciente

NASDAQ
AZN
AstraZeneca
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados